share_log

和鉑醫藥-B:自願公告 - B7H4X4-1BB雙特異性抗體獲新藥研究批准在中國開展I期臨床試驗

HBM HOLDINGS-B: VOLUNTARY ANNOUNCEMENT - IND APPROVAL FOR COMMENCEMENT OF PHASE I TRIAL OF B7H4X4-1BB BISPECIFIC ANTIBODY IN CHINA

Jun 8, 2022 04:30
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more